These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 22703804)

  • 1. Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma.
    Lautz TB; Naiditch JA; Clark S; Chu F; Madonna MB
    J Pediatr Surg; 2012 Jun; 47(6):1267-71. PubMed ID: 22703804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
    Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR
    Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
    Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
    Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of vorinostat on the development of resistance to doxorubicin in neuroblastoma.
    Lautz TB; Jie C; Clark S; Naiditch JA; Jafari N; Qiu YY; Zheng X; Chu F; Madonna MB
    PLoS One; 2012; 7(7):e40816. PubMed ID: 22829886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo.
    Hrzenjak A; Moinfar F; Kremser ML; Strohmeier B; Petru E; Zatloukal K; Denk H
    Mol Cancer; 2010 Mar; 9():49. PubMed ID: 20202195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter?
    Modesitt SC; Parsons SJ
    Gynecol Oncol; 2010 Nov; 119(2):351-7. PubMed ID: 20673975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effect of long-term drug selection with doxorubicin and vorinostat on neuroblastoma cells with cancer stem cell characteristics.
    Zheng X; Naiditch J; Czurylo M; Jie C; Lautz T; Clark S; Jafari N; Qiu Y; Chu F; Madonna MB
    Cell Death Dis; 2013 Jul; 4(7):e740. PubMed ID: 23887631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy of conditionally replicating adenovirus and histone deacetylase inhibitors.
    Kim DR; Park MY; Lim HJ; Park JS; Cho YJ; Lee SW; Yoon HI; Lee JH; Kim YS; Lee CT
    Int J Mol Med; 2012 Feb; 29(2):218-24. PubMed ID: 22075951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
    Kim JS; Lee SC; Min HY; Park KH; Hyun SY; Kwon SJ; Choi SP; Kim WY; Lee HJ; Lee HY
    Cancer Lett; 2015 Jun; 361(2):197-206. PubMed ID: 25721083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels.
    Mahalingam D; Medina EC; Esquivel JA; Espitia CM; Smith S; Oberheu K; Swords R; Kelly KR; Mita MM; Mita AC; Carew JS; Giles FJ; Nawrocki ST
    Clin Cancer Res; 2010 Jan; 16(1):141-53. PubMed ID: 20028765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
    Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steink├╝hler C; Jones P
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The histone deacetylase inhibitor vorinostat selectively sensitizes fibrosarcoma cells to chemotherapy.
    Sampson ER; Amin V; Schwarz EM; O'Keefe RJ; Rosier RN
    J Orthop Res; 2011 Apr; 29(4):623-32. PubMed ID: 20957741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
    Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of vorinostat and adenovirus-TRAIL exhibits a synergistic antitumor effect by increasing transduction and transcription of TRAIL in lung cancer cells.
    Kim DR; Park MY; Lee CS; Shim SH; Yoon HI; Lee JH; Sung MW; Kim YS; Lee CT
    Cancer Gene Ther; 2011 Jul; 18(7):467-77. PubMed ID: 21455254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53.
    Huang JM; Sheard MA; Ji L; Sposto R; Keshelava N
    Mol Cancer Ther; 2010 Dec; 9(12):3289-301. PubMed ID: 21159612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.
    Hwang JJ; Kim YS; Kim T; Kim MJ; Jeong IG; Lee JH; Choi J; Jang S; Ro S; Kim CS
    Invest New Drugs; 2012 Aug; 30(4):1434-42. PubMed ID: 21773733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model.
    Saucier JM; Yu J; Gaikwad A; Coleman RL; Wolf JK; Smith JA
    J Oncol Pharm Pract; 2007 Mar; 13(1):39-45. PubMed ID: 17621566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.
    Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMullan C; Miller JW; Marks PA; Mitsiades N
    Invest Ophthalmol Vis Sci; 2009 Sep; 50(9):4072-9. PubMed ID: 19387079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.